Keros Therapeutics (NASDAQ:KROS) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $40.00 price target on the stock.

A number of other equities research analysts also recently commented on KROS. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Wedbush downgraded Keros Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $47.00 to $15.00 in a research note on Friday, January 17th. Piper Sandler decreased their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, January 17th. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Wells Fargo & Company reduced their target price on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $9.55 on Tuesday. The stock has a fifty day moving average price of $11.10 and a 200 day moving average price of $33.64. Keros Therapeutics has a 1-year low of $9.41 and a 1-year high of $72.37. The company has a market cap of $387.37 million, a PE ratio of -1.83 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Several large investors have recently bought and sold shares of KROS. AlphaQuest LLC boosted its position in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its holdings in Keros Therapeutics by 36.7% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after acquiring an additional 1,033 shares in the last quarter. Virtus ETF Advisers LLC raised its position in Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Keros Therapeutics by 59.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock valued at $312,000 after purchasing an additional 1,994 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Keros Therapeutics in the fourth quarter valued at approximately $90,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.